Ask Warren

JONBUR Research · Initiation

You're reading an earlier report from Oct 18, 2026. See the latest report

DuChemBio · 176750 · Biotech & Pharma

DuChemBio: Sharp One-Month Rally Leaves Shares Well Above a Model Estimate, Backed by Steady Profits

Why this report

Start of coverage: written when a reader opened this company and there was no report yet.

DuChemBio closed at ₩8,600 on 2026-10-16, up 49.8% in a month but down 8.4% over one year, with a market value of about ₩245.0B. Profits are solid, with a 19.4% operating margin, yet the price sits well above the model estimate of ₩5,300 per share.

Written Oct 18, 2026 · Data as of Oct 16, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

Thesis

The data supports a profitable, growing small-cap: trailing revenue of ₩41.5B, an operating margin of 19.4% and a return on equity of 14.4%. The balance sheet is modest in leverage, with cash above borrowings.

The recent price move looks news-driven. Headlines on 2026-10-15 and 2026-10-16 link the jump to hopes for domestic approval of an Alzheimer's treatment from Lilly. The data does not show whether that approval will happen or how it would affect the company's earnings.

The filings also show a merger decision in July and a merger completion report on 2026-10-02. The data gives no details on the merger's terms or effect on the numbers, so trailing figures may not reflect the combined business. Retail investors were net buyers over 20 days (about ₩245M) while foreigners were net sellers (about ₩247M), though both amounts are small.

Business overview

DuChemBio is listed on KOSDAQ in the Biotech & Pharma sector. It was founded on 2002-11-06 and listed on 2024-12-20. It has 28,488,720 listed shares and a market capitalisation of about ₩245.0B.

Revenue was ₩35.6B in 2024 and ₩38.6B in 2025, growth of 8.3%. Trailing revenue to H1 2026 was ₩41.5B. Foreign ownership is low at 0.8%, up from 0.7% sixty days earlier. Short balance data is not available.

Every earlier JONBUR Research report and update note on DuChemBio, with Pro.

Unlock with Pro

Model estimate of fair value

Bear
₩3,711
-47%
Base
₩5,300
-25%
Bull
₩7,857
+12%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Base case of the 5-year discounted cash flow model on the stock's Valuation tab (statements TTM to H1 2026; discount rate 7.5%). Bear and Bull move the main assumptions by fixed steps. See and change the assumptions

Filings and data used

Report history

  1. Oct 25, 2026Update noteModel fair value changeDuChemBio: Model Fair Value Estimate Cut 24.4% to ₩4,009 per Share
  2. Oct 18, 2026InitiationStart of coverage (reader request)DuChemBio: Sharp One-Month Rally Leaves Shares Well Above a Model Estimate, Backed by Steady Profits

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information